RBX1 and COVID-19: Recently, Lenalidomide, a CRBN/RBX1 inhibitor, has shown protective roles in multiple COVID-19 infected myeloma patients against progressing into severe infections[32], and suggests the emergence of this particular platelet subpopulation may drive the disease severity in COVID-19 infection.